Evidence map›Paper›PMID 42283231›Full record

Trial reportAmerican journal of hematology2026

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma.

Julio C Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach, Izidore S Lossos, Nirav Shah, Sarit Assouline, Adam J Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham and 8 more

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03671018 (An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03671018 phase1 / phase2active not recruitingnot on this map

An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma

TypeinterventionalSponsorHoffmann-La RocheRan2018 to 2025Enrolled422ConditionsB-cell Non-Hodgkin LymphomaArmsMosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin, Tocilizumab, Rituximab
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Julio C ChavezDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida, USA.ORCID https://orcid.org/0000-0002-2045-6238
Mariana Bastos-OreiroDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Catherine DiefenbachClinical Lymphoma Program, Perlmutter Cancer Center at NYU Langone Health, New York, New York, USA.
Izidore S LossosDivision of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida, USA.ORCID https://orcid.org/0000-0002-9346-9013
Nirav ShahDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID https://orcid.org/0000-0002-4336-1071
Sarit AssoulineDivision of Hematology, Jewish General Hospital, Montreal, Quebec, Canada.
Adam J OlszewskiDepartment of Medicine, The Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Seema NaikDepartment of Medicine, Penn State Cancer Institute, Hershey, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-9859-151X
Nilanjan GhoshDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, USA.ORCID https://orcid.org/0000-0002-3848-6136
Song PhamHoffmann-La Roche Ltd., Mississauga, Ontario, Canada.
Michael C WeiGenentech, Inc., South San Francisco, California, USA.
Connie BatleviGenentech, Inc., South San Francisco, California, USA.
Iris ToGenentech, Inc., South San Francisco, California, USA.
Wahib EadGenentech, Inc., South San Francisco, California, USA.
Sneha MakadiaGenentech, Inc., South San Francisco, California, USA.
Elicia PenuelGenentech, Inc., South San Francisco, California, USA.
Jing JingGenentech, Inc., South San Francisco, California, USA.
Lihua E BuddeDivision of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA.

Funding

F. Hoffmann-La Roche Ltd
6 · The paper itself

Abstract

Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R-Pola) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun-Pola), with > 2 years of follow-up. Patients with R/R LBCL and ≥ 1 prior line of therapy were randomized to receive Mosun-Pola or R-Pola. Mosunetuzumab was administered subcutaneously with Cycle (C) 1 step-up dosing (5/45/45 mg) then 45 mg on C2 Day (D) 1-C8D1 (21-day cycles). Polatuzumab vedotin (1.8 mg/kg) was given intravenously (IV) on D1 of C1-6. Rituximab IV (375 mg/m

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseRituximabAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedFemaleHumansImmunoconjugatesInjections, SubcutaneousMaleMiddle AgedRecurrenceAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedImmunoconjugatespolatuzumab vedotinRituximabB‐cell non‐Hodgkin lymphomalarge B‐cellmosunetuzumabpolatuzumab vedotinsubcutaneous

Identifiers

PMID42283231
PMCPMC13428363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.